Cyclerion Therapeutics, Inc.
TREATMENT OF CNS DISEASES WITH sGC STIMULATORS
Last updated:
Abstract:
The present disclosure relates to the use of stimulators of soluble guanylate cyclase (sGC), pharmaceutically acceptable salts thereof and pharmaceutical formulations or dosage forms comprising them, alone or in combination with one or more additional agents, for the treatment of various CNS diseases, wherein an increase in sGC stimulation, or an increase in the concentration of nitric oxide (NO), or cyclic guanosine 3',5'-monophosphate (cGMP) or both, or an upregulation of the NO pathway is desirable.
Status:
Application
Type:
Utility
Filling date:
7 Nov 2017
Issue date:
14 Nov 2019